Mi­cro­bio­me play­er uBio­me puts founders on leave, in­ter­im CEO promis­es to as­sist in fed­er­al probe

7 years ago
People

Why did GSK kill two vac­cine R&D pro­grams? CEO Em­ma Walm­s­ley is glad you asked

7 years ago
R&D

Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

7 years ago
News Briefing

Al­ler­gan CEO Saun­ders hangs on to chair­man's ti­tle, win­ning share­hold­er sup­port — but not by a big enough mar­gin to ...

7 years ago
People

Man­u­fac­tur­ing is­sues hob­ble Heron's quest to mar­ket its long-act­ing non-opi­oid painkiller

7 years ago
Pharma

173 to 1: Bris­tol-My­ers chief Caforio picked up a $19.4M com­pen­sa­tion deal af­ter lead­ing the charge for $74B Cel­gene ...

7 years ago
People

Man­u­fac­tur­ing con­cerns spike Nabri­va’s plans to launch its first an­tibi­ot­ic — for now

7 years ago
R&D

Gilead los­es yet an­oth­er ex­ec­u­tive as CFO Wash­ing­ton joins ex­o­dus, jump­ing to Al­pha­bet board

7 years ago
People

'So­phis­ti­cat­ed' cy­berthieves hacked in­to Charles Riv­er Labs and made off with clients’ drug da­ta

7 years ago
Outsourcing

FDA adds boxed warn­ings to in­som­nia med­i­cines fol­low­ing in­juries, deaths

7 years ago
Pharma

Roche spins out Nim­ble Ther­a­peu­tics to cap­i­tal­ize on pep­tide drug dis­cov­ery, with $10M sup­port from Tele­graph Hill ...

7 years ago
Startups

Share price blitzed, an­a­lysts in an up­roar af­ter lead PhI­II drug im­plodes — and Bio­gen un­veils a $2.5M raise for ...

7 years ago
People

The right mix mat­ters in bio­phar­ma lead­er­ship

7 years ago
Biotech Voices

As Mer­ck cel­e­brates ris­ing flow of Keytru­da cash, ex­ecs plot fa­cil­i­ty shut­downs, lay­offs in $1.2B re­or­ga­ni­za­tion

7 years ago
Pharma

As­traZeneca teams with Benev­o­len­tAI on dis­cov­ery, re­search; Cam­bridge spin­out rais­es seed cash for pro­tein ...

7 years ago
News Briefing

Top 5 Chi­nese play­ers: What does Ever­est's land­mark deal with Im­munomedics say about the flur­ry of in-li­cens­ing to ...

7 years ago
China

In­cyte pulls away 'dam­aged good­s' baric­i­tinib to fo­cus on in­ter­nal pipeline

7 years ago
R&D

Suf­fer­ing a se­ries of set­backs, Eli Lil­ly's on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

7 years ago
R&D

As Eli Lil­ly suf­fers a sharp set­back on rev­enue pro­jec­tions, the on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top ...

7 years ago
R&D

Co­di­ak Bio­sciences out­lines a new fo­cus for its ex­o­some plat­form in $86M IPO fil­ing

7 years ago
Financing

An­a­lyst pens a barbed note to Bio­gen: Shed cau­tion, dump Alzheimer’s and re­tool at the top — go bold

7 years ago
People

Vow­ing to spark a rev­o­lu­tion in small mol­e­cule R&D, Vi­vid­ion equips it­self with an ex­tra $82M for the fi­nal stretch ...

7 years ago
Financing
Startups

A biotech fledg­ling cross-bred in France and Switzer­land launch­es to take on liv­er prob­lems of glob­al di­men­sions

7 years ago
Financing
Startups

EU uni­ver­si­ties are mis­er­ably lax at re­port­ing clin­i­cal tri­al re­sults, analy­sis sug­gests

7 years ago
R&D
First page Previous page 938939940941942943944 Next page Last page
A service from the Financial Times